Circulating tumor cells (CTC) are cells that disseminate from a primary tumor throughout the circulatory system and that can ultimately form secondary tumors at distant sites. CTC count can be used to follow disease progression based on the correlation between CTC concentration in blood and disease severity 1 . As a treatment tool, CTC could be studied in the laboratory to develop personalized therapies. To this end, CTC isolation must cause no cellular damage, and contamination by other cell types, particularly leukocytes, must be avoided as much as possible 2 . Many of the current techniques, including the sole FDA-approved device for CTC enumeration, destroy CTC as part of the isolation process (for more information see Ref. 2). A microfluidic device to capture viable CTC is described, consisting of a surface functionalized with E-selectin glycoprotein in addition to antibodies against epithelial markers 3 . To enhance device performance a nanoparticle coating was applied consisting of halloysite nanotubes, an aluminosilicate nanoparticle harvested from clay 4 . The E-selectin molecules provide a means to capture fast moving CTC that are pumped through the device, lending an advantage over alternative microfluidic devices wherein longer processing times are necessary to provide target cells with sufficient time to interact with a surface. The antibodies to epithelial targets provide CTC-specificity to the device, as well as provide a readily adjustable parameter to tune isolation. Finally, the halloysite nanotube coating allows significantly enhanced isolation compared to other techniques by helping to capture fast moving cells, providing increased surface area for protein adsorption, and repelling contaminating leukocytes 3,4 . This device is produced by a straightforward technique using off-the-shelf materials, and has been successfully used to capture cancer cells from the blood of metastatic cancer patients. Captured cells are maintained for up to 15 days in culture following isolation, and these samples typically consist of >50% viable primary cancer cells from each patient. This device has been used to capture viable CTC from both diluted whole blood and buffy coat samples. Ultimately, we present a technique with functionality in a clinical setting to develop personalized cancer therapies.
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Video Link
The video component of this article can be found at http://www.jove.com/video/4248/
Protocol
The following protocol is for the production of a single microtube device.
Preparation of Halloysite Nanotube Solution
1. Sonicate (10-13 W (rms)) 250 μL halloysite nanotube solution (6.6 wt% in water) 30 sec. Cool solution with cold water and repeat sonication once. Cool again. 2. Draw sonicated solution into a syringe, attach a 0.45 μm syringe filter, and filter solution into clean microfuge tube. Vortex the solution occasionally to maintain homogeneity.
1. Prepare a solution of 10 μg/mL protein G in 1X Dulbecco's phosphate buffered saline (PBS, pH 7.0 -7.2). Draw 50 μL PBS through microtube and then draw 50 μL of the protein-G solution and allow to incubate for 1.5 hr at RT. 2. Prepare a solution containing 5 μg/mL E-selectin-IgG and 50 μg/mL antibody (anti-EpCAM for most cancer samples, anti-PSMA for prostate cancer samples) in PBS. Draw 50 μL of the E-selectin and antibody solution into the microtube and allow to incubate for 2 hr at RT. 3. Nonspecific cellular adhesion is blocked with 5% milk protein. Prepare a solution of 5% (w/v) milk protein in PBS. Draw 50 μL milk protein solution into the microtube and allow to incubate for 1 hr at RT. 4. Draw 50 μL PBS into tube and leave at RT until blood or buffy coat samples are ready for processing. 5. 10 min prior to using the microtube for isolation, draw 50 μL PBS that has been saturated with Ca 2+ ("PBS+") to activate the selectin molecules.
Preparation of samples for cell isolation
1. Draw or obtain 10 mL blood from patient into heparinized tube. 2. Place 10 mL Ficoll-Paque lymphocyte isolation solution into 50 mL centrifuge tube. Gently layer 10 mL whole blood on top of Ficoll so as not to mix the blood and Ficoll. 3. Centrifuge at 2000x g for 15 min at 4 °C with minimal deceleration. 4. Remove the buffy coat layer and place in new tube. 5. Wash buffy coat with PBS (centrifuge at 230x g for 10 min, discard the supernatant). 6. Gently resuspend cells with 1 mL RBC lysis buffer and incubate for 10 min at RT to lyse erythrocytes. 7. Add 10 mL PBS, mix gently, and centrifuge at 230x g for 10 min. Discard the supernatant and gently resuspend the pellet in 3 to 4 mL PBS+.
Cell isolation
1. Attach one end of the functionalized microtube to a 5 mL syringe using IDEX adaptors. Accutase. Gently perfuse enough Accutase into the microtube to fill (~50 μL) and allow to incubate at RT for 10 min. 7. Attach a syringe prefilled with 1 mL of growth media (79% RPMI, 20% FBS, 1% penicillin streptomycin) and perfuse into microtube, collecting effluent into tissue culture treated well plate. 8. Culture cells at 37 °C and 5% CO 2 under humidified conditions.
Representative Results
The goal of this technique is to isolate viable cancer cells from the blood of cancer patients. Several methods exist to identify cancer cells in culture; a necessary verification of device success. We have chosen to stain cells in culture with antibodies against epithelial moieties such as EpCAM (epithelial cellular adhesion molecule) or PSMA (prostate specific membrane antigen), in addition to DAPI to identify intact cell nuclei (Fig. 2 and 3) . The number of cancer cells captured using this technique is necessarily a function of the number of CTCs in the starting sample, and patient variability can be high. In processing samples taken from patients diagnosed with stage IV cancers, we routinely capture between 100 and 500 cancer cells per tube of blood, at purities >50%. Immediately following isolation, greater numbers of contaminating leukocytes may be present. However these numbers will be depleted following incubation in culture medium for up to 5 days. 
Discussion
It is often the case that the early steps in the discovery of new cancer therapeutics utilize cancer cell lines, which bear questionable resemblance to primary cancer cells yet remain in use due to their ease of use in the laboratory. Research into the development of new cancer therapies would be expedited if primary human cancer cells were utilized early in novel research. CTC are the most easily accessible type of cancer cell, due to their presence in blood and the ease of a standard blood draw. In addition, circulating tumor cells represent a necessary step in the process of metastasis 5, 6 , so their relevance to the disease and utility for targeting new drugs is clear. Isolation of CTC from blood in vitro is complicated by their low concentrations: on the order of one per million leukocytes or one per billion erythrocytes 7 . The majority of current methods for detecting CTC in blood, including the only FDA-approved technique CellSearch(Veridex), damage or destroy cells in the detection process, precluding use beyond enumeration. The method described above does not compromise cell viability and thus opens the door for future clinical research on cancer. As the recovery of intact cells is the goal of this technique, it is imperative that cells be handled with care, especially during blood separation steps.
There are a number of tunable parameters in this system that could be altered to achieve improved yield depending on critical characteristics such as cancer type. In the steps described above, we had chosen to use EpCAM as a CTC-specific antibody for all cancer types except when processing prostate cancer samples, wherein anti-PSMA was used. Further substitutions of cancer-specific antibodies can certainly be used to improve performance for individual patients. Furthermore, selectin and antibody concentrations can be altered to enhance capture 8 .
An essential feature of the device is the incorporation of E-selectin molecules onto the surface. E-selectin is normally expressed on the luminal surface of endothelial cells and function to recruit fast moving leukocytes to sites of inflammation. Flowing leukocytes bind transiently to selectin molecules, resulting in a slower, rolling behavior that facilitates slower and stronger binding of the cell to the endothelium by integrins. Convincing experimental evidence exists that makes the case that CTC can extravasate by a similar mechanism .Thus our device physiologically mimics a venule to biomimetically capture flowing CTC without inflicting cellular injury.
Enhanced device performance can be attributed to the addition of the halloysite nanotube coating to the luminal surface of the device. Previous studies have shown that there are three major components of the nanotube coating that allows for improved functionality. First, the nanotube coating provides increased surface area, allowing for greater protein deposition onto the surface 4 . Second, in performing atomic force microscopy on the nanotube coating we have determined that individual nanotubes protrude from the surface into the flow. This allows selectin molecules to be presented as much as one micron above the surface so that cells can be captured and recruited to the surface earlier in their trajectory through the tube 4 . Finally, the halloysite nanotube coating is able to prevent leukocyte adhesion and spreading on the surface, allowing for a reduced number of leukocytes captured along with the CTC and thus greater subsequent CTC purities 
